Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IRD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| 0.75% Phentolamine Ophthalmic Solution | Vision Loss Night | Phase 3 · NCT07140783 | Recruiting |
| Pilocarpine | Presbyopia | Phase 3 · NCT05646719 | Completed |
| phentolamine ophthalmic solution 0.75% | Mydriasis | Phase 3 · NCT05134974 | Completed |
| phentolamine ophthalmic solution 0.75%, a… | Mesopic Vision | Phase 3 · NCT06349759 | Completed |
| Phentolamine Opthalmic Solution 0.75% | Presbyopia | Phase 3 · NCT05646719 | Completed |
| AAV8.hLCA5 | LCA5 | Phase 1/2 · NCT05616793 | Recruiting |
| Erenapurstat (APX3330) | Diabetic Retinopathy | Phase 2 · NCT04692688 | Completed |
| OPGx-RDH12 | Leber Congenital Amaurosis | Phase 1/2 · NCT07681778 | Recruiting |
| Phentolamine Mesylate Ophthalmic Solution 0.5% | Night Vision Complaints | Phase 2 · NCT01703559 | Completed |
| Phentolamine Mesylate Ophthalmic Solution 1.0% | Night Vision Complaints | Phase 2 · NCT01703559 | Completed |
| Phentolamine Mesylate Ophthalmic Solution 1% | Mydriasis | Phase 2 · NCT04024891 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IRD holds $89M in cash and short-term investments (as of Sep 30, 2026) and burns about $13M/quarter from operations, an estimated runway of 20.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 47 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IRD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | Institution (13G, 5%+) | 10,086,525 | 10.44% | 2026-09-30 |
| BALYASNY ASSET MANAGEMENT L.P. | Institution (13G, 5%+) | 6,120,982 | 6.33% | 2026-09-30 |
| Caligan Partners LP | Institution (13G, 5%+) | 5,960,972 | 6.17% | 2026-09-30 |
| Cormorant Asset Management, LP | Institution (13G, 5%+) | 5,500,000 | 5.69% | 2026-09-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,044,847 | 5.22% | 2026-09-30 |
| Nantahala Capital Management, LLC | Institution (13G, 5%+) | 4,839,225 | 5.01% | 2026-03-31 |
| Boxer Capital Management, LLC | Institution (13G, 5%+) | 4,533,660 | 4.69% | 2026-09-30 |
| Bios Capital Management, LP | Institution (13F) | 3,683,429 | 3.81% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 3,273,451 | 3.39% | 2026-09-30 |
| Foundation Fighting Blindness Retinal De Director |
Insider | 3,236,171 | 3.35% | 2026-09-30 |
| Marshall Wace LLP | Institution (13F) | 3,161,606 | 3.27% | 2026-09-30 |
| Cam Gallagher Director |
Insider | 2,883,111 | 2.98% | 2026-09-08 |
Share count 96,654,336 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-03 filed 2026-11-05 |
Magrath George |
Sale (S) | 28,258 | $3.90 | 2,010,636 |
| 2026-10-23 filed 2026-10-27 |
YERXA BENJAMIN R |
Sale (S) | 7,669 | $3.55 | 696,437 |
| 2026-10-23 filed 2026-10-27 |
YERXA BENJAMIN R |
Sale (S) | 25,520 | $3.53 | 670,917 |
| 2026-10-23 filed 2026-10-27 |
SCHACHLE JOSEPH K |
Sale (S) | 4,767 | $3.57 | 286,673 |
| 2026-10-23 filed 2026-10-27 |
Magrath George |
Sale (S) | 9,591 | $3.59 | 2,038,894 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-10-17 | Phentolamine Ophthalmic Solution 0.75% | sNDA | -27.3% | — | — |
| 2026-03-10 | — | NDA | +84.9% | +1.7% | +8.8% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IRD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →